Where does Kilitch Drugs (India) make most of its revenue?

Export: 56% of revenue by region in fiscal year 2025, followed by India (44%).

What companies are similar to Kilitch Drugs (India)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Lincoln Pharmaceuticals Limited (LINCOLN.NS), Bafna Pharmaceuticals Limited (BAFNAPH.NS), Themis Medicare Limited (THEMISMED.NS), Albert David Limited (ALBERTDAVD.NS).

Kilitch Drugs (India) Limited (KILITCH.NS) Stock

About Kilitch Drugs (India) Limited

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, anti...

At a glance

In Q3 2026 (the quarter ended December 31, 2025) revenue was 538.08 million INR, down 4.2% from a year before. Export was its largest region in fiscal year 2025, with 56% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.